SBS

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期三, 二月 28, 2024

Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.

Key Points: 
  • Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.
  • ET, to discuss fourth quarter and full year 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
  • The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP operating expenses, and adjusted EBITDA.
  • Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.

LiVDerm’s 22nd Annual South Beach Symposium Achieves Outstanding Success in Miami Beach

Retrieved on: 
星期四, 二月 22, 2024

Hosted side by side, these two annual events brought together leading experts, practitioners, and industry professionals to exchange knowledge, share insights, and advance dermatologic care.

Key Points: 
  • Hosted side by side, these two annual events brought together leading experts, practitioners, and industry professionals to exchange knowledge, share insights, and advance dermatologic care.
  • Attendees had the opportunity to engage with renowned faculty members and explore the latest advances in both medical and cosmetic dermatology.
  • The enhanced exhibition hall served as a hub of innovation and networking, further enriching the symposium experience for all present.
  • "We are thrilled with the success of both symposia and the impact they've had on advancing dermatologic education and patient care.

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on: 
星期四, 二月 29, 2024

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF).

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF).
  • Based on these results, Ironwood plans to submit a new drug application (NDA) and other regulatory filings for apraglutide for use in adult patients with SBS who are dependent on PS.
  • The global, multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of weekly subcutaneous injections of apraglutide in adult patients with SBS-IF.
  • Topline safety results were generally consistent with the safety profile demonstrated in apraglutide studies to date.

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

Retrieved on: 
星期五, 二月 23, 2024

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference.
  • ASPEN is being held from March 2-5, 2024, in Tampa, Florida.
  • SBS is a serious and chronic condition where there is diminished absorptive capacity for fluids and/or nutrients, typically resulting from extensive intestinal resection.
  • “These findings continue to deepen our understanding of GLP-2 and the potential of apraglutide to help adult patients with SBS who are dependent on PS, including those with colon-in-continuity.

Axway Announces Entering Into Exclusive Discussions to Acquire Most of Sopra Banking Software Activities

Retrieved on: 
星期三, 二月 21, 2024

Axway (Paris:AXW) today announces entering into exclusive discussions regarding the potential acquisition of most of Sopra Banking Software (“SBS”) activities, which are currently part of Sopra Steria Group.

Key Points: 
  • Axway (Paris:AXW) today announces entering into exclusive discussions regarding the potential acquisition of most of Sopra Banking Software (“SBS”) activities, which are currently part of Sopra Steria Group.
  • Axway would acquire the SBS activities concerned by the operation for an enterprise value of €330m.
  • Sopra Steria granted exclusive rights to Axway and Sopra GMT to negotiate the envisaged transactions.
  • Pierre Pasquier, Chairman of Axway, Sopra Steria and Sopra GMT, declared:
    "Axway's proposed acquisition of most of SBS's activities represents an undeniable strategic opportunity for both companies.

Sharp Business Systems Named to CRN's MSP 500 List

Retrieved on: 
星期四, 三月 7, 2024

MONTVALE, N.J., March 7, 2024 /PRNewswire/ -- Sharp Imaging and Information Company of America (SIICA), a division of Sharp Electronics Corporation (SEC), today announced that CRN ® , a brand of The Channel Company , has named its direct sales division, Sharp Business Systems (SBS), to its Managed Service Provider (MSP) 500 list in the Elite 150 category for 2024.

Key Points: 
  • MONTVALE, N.J., March 7, 2024 /PRNewswire/ -- Sharp Imaging and Information Company of America (SIICA), a division of Sharp Electronics Corporation (SEC), today announced that CRN ® , a brand of The Channel Company , has named its direct sales division, Sharp Business Systems (SBS), to its Managed Service Provider (MSP) 500 list in the Elite 150 category for 2024.
  • The MSP 500 list compiled by CRN serves as a comprehensive guide to identifying and recognizing the top Managed Service Providers (MSPs) in North America.
  • Sharp was selected to the MSP 500 list because of the robust portfolio of managed IT services that it offers to a variety of vertical industries, ensuring efficiency and productivity.
  • The annual MSP 500 list is divided into three sections: the MSP Pioneer 250, MSP Elite 150, and the Managed Security 100.

NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization

Retrieved on: 
星期三, 三月 6, 2024

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.

Key Points: 
  • The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
  • "The objectives pursued by NanoMosaic are positive steps forward for a space desperate for a fit-for-purpose tool that can be standardized throughout the entire gene therapy development and manufacturing processes.
  • "NanoMosaic is excited to offer a unique solution to a challenging and fast-growing gene therapy market," said Qimin Quan, PhD, co-founder and Chief Scientific Officer.
  • NanoMosaic will feature the platform and unique gene therapy applications in a live broadcast scientific webinar alongside industry leaders on March 26, 2024, hosted by Genetic Engineering News (GEN).

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Retrieved on: 
星期四, 二月 15, 2024

Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.

Key Points: 
  • Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.
  • Operating expenses in the fourth quarter of 2023 were $80.0 million, compared to $38.8 million in the fourth quarter of 2022.
  • Adjusted EBITDA was $39.9 million in the fourth quarter of 2023, compared to $68.7 million in the fourth quarter of 2022.
  • Ironwood generated $35.8 million in cash from operations in the fourth quarter of 2023, compared to $79.2 million in cash from operations in the fourth quarter of 2022.

Doxing or in the public interest? Free speech, ‘cancelling’ and the ethics of the Jewish creatives’ WhatsApp group leak

Retrieved on: 
星期三, 二月 14, 2024

Not all of members knew they had been added to the group at first, and many didn’t participate in the conversations that resulted in the leak.

Key Points: 
  • Not all of members knew they had been added to the group at first, and many didn’t participate in the conversations that resulted in the leak.
  • Last week, a transcript from the group chat was leaked and uploaded onto social media by pro-Palestinians, including the writer Clementine Ford.
  • The leak gives rise to a complex tangle of contemporary ethical issues, including concerns with privacy, doxing, free speech and “cancelling”.


Read more:
Israel-Hamas war: What is Zionism? A history of the political movement that created Israel as we know it

Privacy and public interest

  • The WhatsApp group was a private one, where group members would have had a reasonable expectation that their conversation would not be made public.
  • Violating people’s privacy (especially through leaking information onto the forever-searchable internet) is always a moral cost.
  • But sometimes that cost must be paid, particularly if the exposure is in the public interest.
  • It could be argued that revealing the WhatsApp group’s activities was in the public interest.

The ethics of doxing

  • It is usually done without the person’s consent, and aims to expose or punish them in some way.
  • A statement from those behind the release asserted no links had been made to members’ addresses, phone numbers or emails, which were all deliberately redacted.
  • However, the release of people’s identities is still a form of doxing and a serious moral concern.
  • Read more:
    What is doxing, and how can you protect yourself?

What was the WhatsApp group doing?


The WhatsApp group conversations were wide-ranging, and some members made statements many might find offensive or upsetting. One part of the group’s activities involved organised letter-writing, including to the employers or publishers of writers or journalists they felt crossed the line into anti-Semitism.

  • Letters can be used to raise awareness of ethical concerns, to share information and ideas, and to persuade.
  • But letters can also do other things, and an innocuous practice can sometimes gradually progress into more fraught territory.
  • They can also try to get people to act in ways that are morally concerning — such as having someone sacked for their political views.

Should artists be protected?


Before the story broke in the media, but after extracts from the group chat began circulating on social media, the Australian Society of Authors Board published a letter noting its “growing concern” that artists and authors in Australia were facing repercussions for expressing their political positions publicly or in their work. The society stated its commitment to freedom of speech (within the limits set by law) and its opposition to attempts to silence or intimidate authors.

  • The society also opposed attempts to intimidate or silence people through hate speech, explicitly noting antisemitism, and anti-Palestinian and anti-Arab rhetoric.
  • Hate speech, racism and bigotry, and harmful disinformation or stereotyping, should be stopped, and speakers should face the consequences of their wrongdoing.
  • What we perceive as dangerous misinformation or harmful speech (like antisemitism or Islamophobia) will inevitably be coloured by our cultural, political and moral worldviews.
  • But it is precisely those who think differently who will disagree with us about what counts as harmful or wrongful speech.

Ethical worries

  • Punishing, undermining and silencing others on the basis of our political beliefs gives rise to two potential ethical worries (both arise with respect to the modern phenomenon of “cancel culture”).
  • Each side declares: “We are a support group nobly taking a stand against harmful bigotry and hate.
  • Now, I have reason to push back against you – to no longer tolerate your speech.
  • Tragically, some isolated individuals – not necessarily connected to the pro-Palestinians – felt justified in going further, even to threats of violence.


Hugh Breakey does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

COCINA'S Parent Company MECENAS Taps Industry Veteran Andrew Polsky as EVP Revenue and Brand Strategy Amidst Growth Surge

Retrieved on: 
星期三, 二月 7, 2024

LOS ANGELES, Feb. 7, 2024 /PRNewswire/ -- COCINA's parent company, minority owned and operated, MECENAS, a preeminent full-stack media company, today announced the appointment of Andrew Polsky as Executive Vice President of Revenue and Brand Strategy. Polsky, a seasoned executive with extensive experience in multicultural digital media, joins MECENAS at a pivotal time to help position the company and all its units into its next phase of sustained growth.

Key Points: 
  • LOS ANGELES, Feb. 7, 2024 /PRNewswire/ -- COCINA 's parent company, minority owned and operated, MECENAS , a preeminent full-stack media company, today announced the appointment of Andrew Polsky as Executive Vice President of Revenue and Brand Strategy.
  • Polsky, a seasoned executive with extensive experience in multicultural digital media, joins MECENAS at a pivotal time to help position the company and all its units into its next phase of sustained growth.
  • "I am truly honored and excited to join my former colleagues and good friends Emi, Fede, Sarah, and the exceptional team at MECENAS," said Polsky.
  • We are confident Andrew will play a pivotal role in advancing MECENAS' revenue streams while strengthening our brand strategy."